Pioglitazone: beyond glucose control

References

• American Diabetes Association. Position statement: standards of medical care in diabetes. Diabetes Care32(Suppl. 1), S13–S61 (2009).
   PubMed Web of Science ®Google Scholar
• Laakso M. Hyperglycemia and cardiovascular disease in Type 2 diabetes. Diabetes48(5), 937–942 (1999).
   PubMed Web of Science ®Google Scholar
• Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA281(14), 1291–1297 (1999).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Bueno H, Hernaez R, Hernandez AV. Type 2 diabetes mellitus and cardiovascular disease in Spain: a narrative review. Rev. Esp. Cardiol.8(Suppl. C), 53C–61C (2008).
   Google Scholar
• Escobar C, Barrios V, Calderón A et al. Diabetes mellitus in hypertensive population attended in primary care in Spain. Blood pressure and lipid control rates. Rev. Clin. Esp.207(5), 221–227 (2007).
   PubMed Web of Science ®Google Scholar
• Stults B, Jones RE. Management of hypertension in diabetes. Diabetes Spectr.19, 25–31 (2006).
   Google Scholar
• Ostergren J, Poulter NR, Sever PS et al. The Anglo–Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with Type II diabetes. J. Hypertens.26(11), 2103–2111 (2008).
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med.348(5), 383–393 (2003).
   PubMed Web of Science ®Google Scholar
• Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in Type 2 diabetes: systematic review and meta-analysis. PLoS One4(7), e6112 (2009).
   PubMed Web of Science ®Google Scholar
• UKPDS Study Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of Type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes44(11), 1249–1258 (1995).
   PubMed Web of Science ®Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care23(11), 1605–1611 (2000).
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with Type 2 diabetes: a double-blind, placebo-controlled study. Horm. Metab. Res.34(10), 589–595 (2002).
   PubMed Web of Science ®Google Scholar
• Herz M, Johns D, Reviriego J et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin. Ther.25(4), 1074–1095 (2003).
   PubMed Web of Science ®Google Scholar
• Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; for The QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet. Med.22(4), 399–405 (2005).
   PubMed Web of Science ®Google Scholar
• Tan MH, Baksi A, Krahulec B et al.; for the GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with Type 2 diabetes. Diabetes Care28(3), 544–550 (2005).
   PubMed Web of Science ®Google Scholar
• Barnett AH. Redefining the role of thiazolidinediones in the management of Type 2 diabetes. Vasc. Health Risk Manag.5(1), 141–151 (2009).
   PubMedGoogle Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROACTIVE study (Prospective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled trial. Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Hanefeld M. Pioglitazone and sulfonylureas: effectively treating Type 2 diabetes. Int. J. Clin. Pract. Suppl.153, 20–27 (2007).
   Google Scholar
• Schöndorf T, Karagiannis E, Posseldt RE, Forst T, Pfützner A. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in Type 2 diabetes patients with insufficient glycemic control by metformin alone – results from a post-marketing surveillance trial under daily routine conditions. Diabetes Technol. Ther.11(6), 379–383 (2009).
   PubMed Web of Science ®Google Scholar
• Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int. J. Clin. Pract.63(6), 912–929 (2009).
   PubMed Web of Science ®Google Scholar
• Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with Type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr. Med. Res. Opin.25(5), 1111–1119 (2009).
   PubMed Web of Science ®Google Scholar
• Hanefeld M. The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes Obes. Metab.11(8), 742–756 (2009).
   PubMed Web of Science ®Google Scholar
• Chogtu B, Singh NP, Chawla S, Gupta U. Impact of glitazones on metabolic and haemodynamic parameters in patients with Type 2 diabetes mellitus. Singapore Med. J.50(4), 395–399 (2009).
   PubMed Web of Science ®Google Scholar
• Aso Y, Hara K, Ozeki N et al. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled Type 2 diabetes. Diabetes Res. Clin. Pract.85(2), 147–152 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. J. Diabetes Complicat. DOI: 10.1016/j.jdiacomp.2009.05.004 (2009) (Epub ahead of print).
   Google Scholar
• Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.24(1), 29–33 (2004).
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors, Endocr. Rev.26(3), 439–451 (2005).
   PubMed Web of Science ®Google Scholar
• Hanefeld M. Pioglitazone and sulfonylureas: effectively treating Type 2 diabetes. Int. J. Clin. Pract. Suppl.153, 20–27 (2007).
   Google Scholar
• Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P. Insulin-based versus triple oral therapy for newly-diagnosed Type 2 diabetes: which is better? Diabetes Care32(10), 1789–1795 (2009).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in Type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr. Med. Res. Opin.22, 1211–1215 (2006).
   PubMed Web of Science ®Google Scholar
• Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA296(21), 2572–2581 (2006).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA299(13), 1561–1573 (2008).
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Banerji M, Bray GA et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr. Disord.9, 17 (2009).
   PubMed Web of Science ®Google Scholar
• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of Type 2 diabetes mellitus. Diabetes58(4), 773–795 (2009).
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes55(2), 517–522 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider F, Vossler S, Franke S, Bär F, Konrad T. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. Int. J. Clin. Pharmacol. Ther.47(5), 311–320 (2009).
   PubMed Web of Science ®Google Scholar
• Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglitazone therapy improves arterial stiffness in patients with Type 2 diabetes mellitus. Metabolism58(6), 739–745 (2009).
   PubMed Web of Science ®Google Scholar
• Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation115(10), 1285–1295 (2007).
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in Type 2 diabetes. Endocr. J.56(5), 691–698 (2009).
   PubMed Web of Science ®Google Scholar
• Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metab.86(7), 3452–3456 (2001).
   PubMed Web of Science ®Google Scholar
• Davidson M, Meyer PM, Haffner S et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with Type 2 diabetes mellitus. Circulation117(16), 2123–2130 (2008).
   PubMed Web of Science ®Google Scholar
• Takagi T, Okura H, Kobayashi Y et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in Type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc. Interv.2(6), 524–531 (2009).
   PubMed Web of Science ®Google Scholar
• Kaneda H, Shiono T, Miyashita Y et al. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. Heart95(13), 1079–1084 (2009).
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in Type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol.46(2), 145–154 (2009).
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROACTIVE): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care27(7), 1647–1653 (2004).
   PubMed Web of Science ®Google Scholar
• Bottomley J, Palmer A, Williams R, Massi-Benedetti M, Dormandy J. PROACTIVE 03: pioglitazone, Type 2 diabetes and reducing macrovascular events – economic implications. Br. J. Diabetes Vasc. Dis.6, 63–70 (2006).
   Google Scholar
• Wilcox R, Bousser M-G, Pirag V et al. PROACTIVE 04: Effects of pioglitazone in patients with Type 2 diabetes with or without previous stroke – results from PROACTIVE (Prospective Pioglitazone Clinical Trial In Macrovascular Events). Stroke38(3), 865–873 (2007).
   PubMed Web of Science ®Google Scholar
• Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; on behalf of the PROACTIVE investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with Type 2 diabetes and previous myocardial infarction – results from PROACTIVE (PROACTIVE 05). J. Am. Coll. Cardiol.49(17), 1772–1780 (2007).
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Bottomley JM, Palmer AJ et al.; on behalf of the PROACTIVE Study Group. PROACTIVE 06: Cost effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet. Med.4(9), 982–1002 (2007).
   Google Scholar
• Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. PROACTIVE 07: Pioglitazone in the treatment of Type 2 diabetes: results of the PROACTIVE study. Vasc. Health Risk Manag.3(4), 355–370 (2007).
   PubMedGoogle Scholar
• Erdmann E, Charbonnel B, Wilcox RG et al.; on behalf of the PROACTIVE investigators. Pioglitazone use and heart failure in patients with Type 2 diabetes and preexisting cardiovascular disease: data from the PROACTIVE study (PROACTIVE 08). Diabetes Care30(11), 2773–2778 (2007).
   PubMed Web of Science ®Google Scholar
• Schneider CA, Ferrannini E, DeFronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in patients with diabetes and chronic kidney disease. J. Am. Soc. Nephr.19(1), 182–187 (2008).
   PubMed Web of Science ®Google Scholar
• Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with Type 2 diabetes: Results from PROACTIVE (PROACTIVE 10). Am. Heart J.155(4), 712–717 (2008).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; on behalf of the PROACTIVE Investigators. Impact of peripheral arterial disease in patients with diabetes – results from PROACTIVE (PROACTIVE 11). Atherosclerosis202(1), 272–281 (2009).
   PubMed Web of Science ®Google Scholar
• Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B; PROACTIVE Investigators. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROACTIVE experience (PROACTIVE 14). Am. J. Cardiol.104(2), 234–239 (2009).
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. Br. Med. J.339, b2942 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Coron. Artery Dis.128(5), 413–423 (2001).
   Google Scholar
• Gupta AK, Smith SR, Greenway FL, Bray GA. Pioglitazone treatment in Type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes. Metab.11(4), 330–337 (2009).
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355(22), 2297–2307 (2006).
   PubMed Web of Science ®Google Scholar
• Chaggar PS, Shaw SM, Williams SG. Thiazolidinediones and heart failure. Diab. Vasc. Dis. Res.6(3), 146–152 (2009).
   PubMed Web of Science ®Google Scholar
• Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with Type 2 diabetes mellitus treated with pioglitazone for 2 years. Clin. Ther.31(1), 74–88 (2009).
   PubMed Web of Science ®Google Scholar
• Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with Type 2 diabetes. Cardiovasc. Diabetol.8, 15 (2009).
   PubMed Web of Science ®Google Scholar
• Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with Type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin. Ther.26(9), 1400–1410 (2004).
   PubMed Web of Science ®Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and Type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet370(9593), 1129–1136 (2007).
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA298(10), 1180–1188 (2007).
   PubMed Web of Science ®Google Scholar
• Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with Type 2 diabetes: an overview of data from PROactive. Drug Saf.32(3), 187–202 (2009).
   PubMed Web of Science ®Google Scholar
• van der Meer RW, Rijzewijk LJ, de Jong HW et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled Type 2 diabetes mellitus. Circulation119(15), 2069–2077 (2009).
   PubMed Web of Science ®Google Scholar
• Liazos E, Broadbent DM, Beare N, Kumar N. Spontaneous resolution of diabetic macular edema after discontinuation of thizolidinediones. Diabet. Med.25(7), 860–862 (2008).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab.93(5), 1696–1701 (2008).
   PubMed Web of Science ®Google Scholar
• Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ177(7), 723–724 (2007).
   PubMed Web of Science ®Google Scholar
• George J, Hannah S 5th, Lang CC. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. Cardiovasc. Ther.27(2), 83–88 (2009).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care32(1), 193–203 (2009).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in Type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia52(1), 17–30 (2009).
   PubMed Web of Science ®Google Scholar
• St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. Curr. Med. Res. Opin.25(6), 1343–1353 (2009).
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in Type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff. Resour. Alloc.7, 9 (2009).
   PubMedGoogle Scholar
• Brändle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in patients with Type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med. Wkly139(11–12), 173–184 (2009).
   PubMed Web of Science ®Google Scholar